nodes	percent_of_prediction	percent_of_DWPC	metapath
Doxorubicin—sarcoma—acquired immunodeficiency syndrome	0.414	1	CtDrD
Doxorubicin—ABCC1—Amprenavir—acquired immunodeficiency syndrome	0.0217	0.0582	CbGbCtD
Doxorubicin—ABCC3—Lamivudine—acquired immunodeficiency syndrome	0.0199	0.0533	CbGbCtD
Doxorubicin—ABCC1—Indinavir—acquired immunodeficiency syndrome	0.0188	0.0502	CbGbCtD
Doxorubicin—ABCC1—Ritonavir—acquired immunodeficiency syndrome	0.0165	0.0441	CbGbCtD
Doxorubicin—ABCC1—Saquinavir—acquired immunodeficiency syndrome	0.0165	0.0441	CbGbCtD
Doxorubicin—ABCC2—Indinavir—acquired immunodeficiency syndrome	0.0139	0.0372	CbGbCtD
Doxorubicin—ABCC1—Lamivudine—acquired immunodeficiency syndrome	0.0122	0.0327	CbGbCtD
Doxorubicin—ABCC2—Ritonavir—acquired immunodeficiency syndrome	0.0122	0.0326	CbGbCtD
Doxorubicin—ABCC2—Saquinavir—acquired immunodeficiency syndrome	0.0122	0.0326	CbGbCtD
Doxorubicin—ABCG2—Nelfinavir—acquired immunodeficiency syndrome	0.0122	0.0326	CbGbCtD
Doxorubicin—CYP2B6—Efavirenz—acquired immunodeficiency syndrome	0.012	0.0322	CbGbCtD
Doxorubicin—CYP2B6—Lopinavir—acquired immunodeficiency syndrome	0.0113	0.0303	CbGbCtD
Doxorubicin—CYP2B6—Nevirapine—acquired immunodeficiency syndrome	0.0113	0.0303	CbGbCtD
Doxorubicin—ABCG2—Ritonavir—acquired immunodeficiency syndrome	0.011	0.0295	CbGbCtD
Doxorubicin—ABCG2—Saquinavir—acquired immunodeficiency syndrome	0.011	0.0295	CbGbCtD
Doxorubicin—ABCG2—Zidovudine—acquired immunodeficiency syndrome	0.0106	0.0283	CbGbCtD
Doxorubicin—CYP2B6—Amprenavir—acquired immunodeficiency syndrome	0.0102	0.0274	CbGbCtD
Doxorubicin—ABCC2—Lamivudine—acquired immunodeficiency syndrome	0.00904	0.0242	CbGbCtD
Doxorubicin—CYP2B6—Nelfinavir—acquired immunodeficiency syndrome	0.00857	0.0229	CbGbCtD
Doxorubicin—ABCG2—Lamivudine—acquired immunodeficiency syndrome	0.00817	0.0219	CbGbCtD
Doxorubicin—CYP2B6—Ritonavir—acquired immunodeficiency syndrome	0.00775	0.0208	CbGbCtD
Doxorubicin—CYP2D6—Efavirenz—acquired immunodeficiency syndrome	0.00581	0.0156	CbGbCtD
Doxorubicin—ABCB1—Lopinavir—acquired immunodeficiency syndrome	0.0058	0.0155	CbGbCtD
Doxorubicin—CYP2D6—Nevirapine—acquired immunodeficiency syndrome	0.00546	0.0146	CbGbCtD
Doxorubicin—CYP2D6—Lopinavir—acquired immunodeficiency syndrome	0.00546	0.0146	CbGbCtD
Doxorubicin—ABCB1—Amprenavir—acquired immunodeficiency syndrome	0.00524	0.014	CbGbCtD
Doxorubicin—CYP2D6—Amprenavir—acquired immunodeficiency syndrome	0.00494	0.0132	CbGbCtD
Doxorubicin—CYP2D6—Delavirdine—acquired immunodeficiency syndrome	0.00494	0.0132	CbGbCtD
Doxorubicin—ABCB1—Indinavir—acquired immunodeficiency syndrome	0.00453	0.0121	CbGbCtD
Doxorubicin—ABCB1—Nelfinavir—acquired immunodeficiency syndrome	0.00439	0.0118	CbGbCtD
Doxorubicin—CYP2D6—Indinavir—acquired immunodeficiency syndrome	0.00426	0.0114	CbGbCtD
Doxorubicin—CYP2D6—Nelfinavir—acquired immunodeficiency syndrome	0.00414	0.0111	CbGbCtD
Doxorubicin—ABCB1—Saquinavir—acquired immunodeficiency syndrome	0.00397	0.0106	CbGbCtD
Doxorubicin—ABCB1—Ritonavir—acquired immunodeficiency syndrome	0.00397	0.0106	CbGbCtD
Doxorubicin—ABCB1—Zidovudine—acquired immunodeficiency syndrome	0.00381	0.0102	CbGbCtD
Doxorubicin—CYP2D6—Ritonavir—acquired immunodeficiency syndrome	0.00374	0.01	CbGbCtD
Doxorubicin—CYP2D6—Saquinavir—acquired immunodeficiency syndrome	0.00374	0.01	CbGbCtD
Doxorubicin—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.00369	0.00989	CbGbCtD
Doxorubicin—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.00347	0.0093	CbGbCtD
Doxorubicin—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.00347	0.0093	CbGbCtD
Doxorubicin—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.00314	0.00841	CbGbCtD
Doxorubicin—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.00314	0.00841	CbGbCtD
Doxorubicin—ABCB1—Lamivudine—acquired immunodeficiency syndrome	0.00295	0.00789	CbGbCtD
Doxorubicin—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.00271	0.00726	CbGbCtD
Doxorubicin—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.00263	0.00705	CbGbCtD
Doxorubicin—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.00238	0.00637	CbGbCtD
Doxorubicin—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.00238	0.00637	CbGbCtD
Doxorubicin—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.00228	0.00611	CbGbCtD
Doxorubicin—SLC22A16—blood—acquired immunodeficiency syndrome	0.000727	0.0116	CbGeAlD
Doxorubicin—SLC22A16—bone marrow—acquired immunodeficiency syndrome	0.000704	0.0112	CbGeAlD
Doxorubicin—RALBP1—blood plasma—acquired immunodeficiency syndrome	0.000672	0.0107	CbGeAlD
Doxorubicin—NOS3—blood plasma—acquired immunodeficiency syndrome	0.000661	0.0106	CbGeAlD
Doxorubicin—AKR1A1—retina—acquired immunodeficiency syndrome	0.000628	0.01	CbGeAlD
Doxorubicin—ABCB8—blood—acquired immunodeficiency syndrome	0.000566	0.00904	CbGeAlD
Doxorubicin—AKR1A1—skin of body—acquired immunodeficiency syndrome	0.000552	0.00882	CbGeAlD
Doxorubicin—CBR3—blood—acquired immunodeficiency syndrome	0.000544	0.0087	CbGeAlD
Doxorubicin—CBR3—vagina—acquired immunodeficiency syndrome	0.000505	0.00807	CbGeAlD
Doxorubicin—ABCB8—lung—acquired immunodeficiency syndrome	0.000496	0.00793	CbGeAlD
Doxorubicin—CBR3—lung—acquired immunodeficiency syndrome	0.000477	0.00763	CbGeAlD
Doxorubicin—NOS1—retina—acquired immunodeficiency syndrome	0.000476	0.00761	CbGeAlD
Doxorubicin—NDUFS2—retina—acquired immunodeficiency syndrome	0.000473	0.00756	CbGeAlD
Doxorubicin—ABCB8—nervous system—acquired immunodeficiency syndrome	0.000459	0.00734	CbGeAlD
Doxorubicin—ABCC3—blood plasma—acquired immunodeficiency syndrome	0.000451	0.00721	CbGeAlD
Doxorubicin—AKR1A1—lymphoid tissue—acquired immunodeficiency syndrome	0.000447	0.00714	CbGeAlD
Doxorubicin—DHCR7—retina—acquired immunodeficiency syndrome	0.000444	0.0071	CbGeAlD
Doxorubicin—ABCB8—central nervous system—acquired immunodeficiency syndrome	0.000442	0.00707	CbGeAlD
Doxorubicin—CBR3—nervous system—acquired immunodeficiency syndrome	0.000442	0.00707	CbGeAlD
Doxorubicin—AKR1A1—digestive system—acquired immunodeficiency syndrome	0.000441	0.00705	CbGeAlD
Doxorubicin—ABCC6—retina—acquired immunodeficiency syndrome	0.000433	0.00692	CbGeAlD
Doxorubicin—CBR3—central nervous system—acquired immunodeficiency syndrome	0.000426	0.0068	CbGeAlD
Doxorubicin—AKR1A1—blood—acquired immunodeficiency syndrome	0.00042	0.00672	CbGeAlD
Doxorubicin—NDUFS2—skin of body—acquired immunodeficiency syndrome	0.000415	0.00664	CbGeAlD
Doxorubicin—NDUFS3—skin of body—acquired immunodeficiency syndrome	0.00041	0.00656	CbGeAlD
Doxorubicin—YWHAG—retina—acquired immunodeficiency syndrome	0.000408	0.00651	CbGeAlD
Doxorubicin—AKR1A1—bone marrow—acquired immunodeficiency syndrome	0.000407	0.0065	CbGeAlD
Doxorubicin—AKR1A1—spinal cord—acquired immunodeficiency syndrome	0.000405	0.00647	CbGeAlD
Doxorubicin—NDUFS7—digestive system—acquired immunodeficiency syndrome	0.000401	0.00641	CbGeAlD
Doxorubicin—DHCR7—skin of body—acquired immunodeficiency syndrome	0.00039	0.00623	CbGeAlD
Doxorubicin—AKR1A1—vagina—acquired immunodeficiency syndrome	0.00039	0.00623	CbGeAlD
Doxorubicin—NDUFS7—blood—acquired immunodeficiency syndrome	0.000382	0.00611	CbGeAlD
Doxorubicin—AURKA—lymphoid tissue—acquired immunodeficiency syndrome	0.000377	0.00603	CbGeAlD
Doxorubicin—AURKA—digestive system—acquired immunodeficiency syndrome	0.000373	0.00596	CbGeAlD
Doxorubicin—NDUFS7—bone marrow—acquired immunodeficiency syndrome	0.00037	0.00591	CbGeAlD
Doxorubicin—AKR1A1—lung—acquired immunodeficiency syndrome	0.000369	0.00589	CbGeAlD
Doxorubicin—NDUFS7—spinal cord—acquired immunodeficiency syndrome	0.000368	0.00588	CbGeAlD
Doxorubicin—RALBP1—retina—acquired immunodeficiency syndrome	0.000368	0.00588	CbGeAlD
Doxorubicin—AURKA—blood—acquired immunodeficiency syndrome	0.000355	0.00568	CbGeAlD
Doxorubicin—NDUFS7—vagina—acquired immunodeficiency syndrome	0.000354	0.00566	CbGeAlD
Doxorubicin—ABCB8—brain—acquired immunodeficiency syndrome	0.000351	0.00561	CbGeAlD
Doxorubicin—AURKA—Cladribine—Abacavir—acquired immunodeficiency syndrome	0.000345	0.168	CbGdCrCtD
Doxorubicin—AURKA—bone marrow—acquired immunodeficiency syndrome	0.000344	0.00549	CbGeAlD
Doxorubicin—AKR1A1—nervous system—acquired immunodeficiency syndrome	0.000341	0.00545	CbGeAlD
Doxorubicin—ABCB8—lymph node—acquired immunodeficiency syndrome	0.000339	0.00542	CbGeAlD
Doxorubicin—CBR3—brain—acquired immunodeficiency syndrome	0.000338	0.0054	CbGeAlD
Doxorubicin—NDUFS2—lymphoid tissue—acquired immunodeficiency syndrome	0.000336	0.00538	CbGeAlD
Doxorubicin—NDUFS7—lung—acquired immunodeficiency syndrome	0.000335	0.00535	CbGeAlD
Doxorubicin—NOS1—digestive system—acquired immunodeficiency syndrome	0.000334	0.00535	CbGeAlD
Doxorubicin—NDUFS2—digestive system—acquired immunodeficiency syndrome	0.000332	0.00531	CbGeAlD
Doxorubicin—NDUFS3—lymphoid tissue—acquired immunodeficiency syndrome	0.000332	0.00531	CbGeAlD
Doxorubicin—AURKA—vagina—acquired immunodeficiency syndrome	0.000329	0.00526	CbGeAlD
Doxorubicin—AKR1A1—central nervous system—acquired immunodeficiency syndrome	0.000329	0.00525	CbGeAlD
Doxorubicin—NDUFS3—digestive system—acquired immunodeficiency syndrome	0.000328	0.00525	CbGeAlD
Doxorubicin—CBR3—lymph node—acquired immunodeficiency syndrome	0.000326	0.00522	CbGeAlD
Doxorubicin—NOS1—blood—acquired immunodeficiency syndrome	0.000319	0.00509	CbGeAlD
Doxorubicin—NDUFS2—blood—acquired immunodeficiency syndrome	0.000317	0.00506	CbGeAlD
Doxorubicin—DHCR7—lymphoid tissue—acquired immunodeficiency syndrome	0.000316	0.00505	CbGeAlD
Doxorubicin—AURKA—Floxuridine—Zidovudine—acquired immunodeficiency syndrome	0.000315	0.154	CbGdCrCtD
Doxorubicin—AURKA—Floxuridine—Stavudine—acquired immunodeficiency syndrome	0.000315	0.154	CbGdCrCtD
Doxorubicin—NDUFS3—blood—acquired immunodeficiency syndrome	0.000313	0.005	CbGeAlD
Doxorubicin—DHCR7—digestive system—acquired immunodeficiency syndrome	0.000312	0.00499	CbGeAlD
Doxorubicin—AURKA—lung—acquired immunodeficiency syndrome	0.000311	0.00498	CbGeAlD
Doxorubicin—NDUFS7—nervous system—acquired immunodeficiency syndrome	0.00031	0.00496	CbGeAlD
Doxorubicin—NOS1—spinal cord—acquired immunodeficiency syndrome	0.000307	0.00491	CbGeAlD
Doxorubicin—NDUFS2—bone marrow—acquired immunodeficiency syndrome	0.000306	0.0049	CbGeAlD
Doxorubicin—NDUFS2—spinal cord—acquired immunodeficiency syndrome	0.000305	0.00488	CbGeAlD
Doxorubicin—NDUFS3—bone marrow—acquired immunodeficiency syndrome	0.000303	0.00484	CbGeAlD
Doxorubicin—CBR1—skin of body—acquired immunodeficiency syndrome	0.000302	0.00482	CbGeAlD
Doxorubicin—NDUFS3—spinal cord—acquired immunodeficiency syndrome	0.000301	0.00482	CbGeAlD
Doxorubicin—NDUFS7—central nervous system—acquired immunodeficiency syndrome	0.000299	0.00477	CbGeAlD
Doxorubicin—DHCR7—blood—acquired immunodeficiency syndrome	0.000297	0.00475	CbGeAlD
Doxorubicin—CBR3—Gemcitabine—Lamivudine—acquired immunodeficiency syndrome	0.000294	0.143	CbGdCrCtD
Doxorubicin—NDUFS2—vagina—acquired immunodeficiency syndrome	0.000293	0.00469	CbGeAlD
Doxorubicin—NDUFS3—vagina—acquired immunodeficiency syndrome	0.00029	0.00463	CbGeAlD
Doxorubicin—YWHAG—lymphoid tissue—acquired immunodeficiency syndrome	0.00029	0.00463	CbGeAlD
Doxorubicin—ABCC6—blood—acquired immunodeficiency syndrome	0.00029	0.00463	CbGeAlD
Doxorubicin—AURKA—nervous system—acquired immunodeficiency syndrome	0.000288	0.00461	CbGeAlD
Doxorubicin—DHCR7—bone marrow—acquired immunodeficiency syndrome	0.000287	0.0046	CbGeAlD
Doxorubicin—DHCR7—spinal cord—acquired immunodeficiency syndrome	0.000286	0.00458	CbGeAlD
Doxorubicin—YWHAG—digestive system—acquired immunodeficiency syndrome	0.000286	0.00457	CbGeAlD
Doxorubicin—NOS1—lung—acquired immunodeficiency syndrome	0.000279	0.00446	CbGeAlD
Doxorubicin—XDH—digestive system—acquired immunodeficiency syndrome	0.000279	0.00446	CbGeAlD
Doxorubicin—AURKA—central nervous system—acquired immunodeficiency syndrome	0.000278	0.00444	CbGeAlD
Doxorubicin—NDUFS2—lung—acquired immunodeficiency syndrome	0.000278	0.00444	CbGeAlD
Doxorubicin—DHCR7—vagina—acquired immunodeficiency syndrome	0.000275	0.0044	CbGeAlD
Doxorubicin—NQO1—retina—acquired immunodeficiency syndrome	0.000275	0.0044	CbGeAlD
Doxorubicin—NDUFS3—lung—acquired immunodeficiency syndrome	0.000274	0.00438	CbGeAlD
Doxorubicin—YWHAG—blood—acquired immunodeficiency syndrome	0.000273	0.00436	CbGeAlD
Doxorubicin—ABCB11—digestive system—acquired immunodeficiency syndrome	0.000273	0.00436	CbGeAlD
Doxorubicin—NOS2—IL12-mediated signaling events—CCL4—acquired immunodeficiency syndrome	0.000267	0.0293	CbGpPWpGaD
Doxorubicin—YWHAG—bone marrow—acquired immunodeficiency syndrome	0.000264	0.00422	CbGeAlD
Doxorubicin—YWHAG—spinal cord—acquired immunodeficiency syndrome	0.000263	0.0042	CbGeAlD
Doxorubicin—AKR1A1—brain—acquired immunodeficiency syndrome	0.000261	0.00417	CbGeAlD
Doxorubicin—DHCR7—lung—acquired immunodeficiency syndrome	0.00026	0.00416	CbGeAlD
Doxorubicin—NOS1—nervous system—acquired immunodeficiency syndrome	0.000259	0.00413	CbGeAlD
Doxorubicin—RALBP1—digestive system—acquired immunodeficiency syndrome	0.000258	0.00413	CbGeAlD
Doxorubicin—NOS3—lymphoid tissue—acquired immunodeficiency syndrome	0.000257	0.00411	CbGeAlD
Doxorubicin—NDUFS2—nervous system—acquired immunodeficiency syndrome	0.000257	0.00411	CbGeAlD
Doxorubicin—NOS3—digestive system—acquired immunodeficiency syndrome	0.000254	0.00406	CbGeAlD
Doxorubicin—NDUFS3—nervous system—acquired immunodeficiency syndrome	0.000254	0.00406	CbGeAlD
Doxorubicin—ABCC6—lung—acquired immunodeficiency syndrome	0.000254	0.00406	CbGeAlD
Doxorubicin—YWHAG—vagina—acquired immunodeficiency syndrome	0.000253	0.00404	CbGeAlD
Doxorubicin—AKR1A1—lymph node—acquired immunodeficiency syndrome	0.000252	0.00403	CbGeAlD
Doxorubicin—NOS1—central nervous system—acquired immunodeficiency syndrome	0.000249	0.00398	CbGeAlD
Doxorubicin—NDUFS2—central nervous system—acquired immunodeficiency syndrome	0.000247	0.00396	CbGeAlD
Doxorubicin—XDH—vagina—acquired immunodeficiency syndrome	0.000246	0.00394	CbGeAlD
Doxorubicin—RALBP1—blood—acquired immunodeficiency syndrome	0.000246	0.00394	CbGeAlD
Doxorubicin—NOS2—Circadian rythm related genes—CARTPT—acquired immunodeficiency syndrome	0.000245	0.0268	CbGpPWpGaD
Doxorubicin—NDUFS3—central nervous system—acquired immunodeficiency syndrome	0.000244	0.00391	CbGeAlD
Doxorubicin—CBR1—lymphoid tissue—acquired immunodeficiency syndrome	0.000244	0.0039	CbGeAlD
Doxorubicin—CYP2B6—blood plasma—acquired immunodeficiency syndrome	0.000243	0.00388	CbGeAlD
Doxorubicin—NOS3—blood—acquired immunodeficiency syndrome	0.000242	0.00387	CbGeAlD
Doxorubicin—NQO1—skin of body—acquired immunodeficiency syndrome	0.000242	0.00386	CbGeAlD
Doxorubicin—CBR1—digestive system—acquired immunodeficiency syndrome	0.000241	0.00386	CbGeAlD
Doxorubicin—DHCR7—nervous system—acquired immunodeficiency syndrome	0.000241	0.00386	CbGeAlD
Doxorubicin—YWHAG—lung—acquired immunodeficiency syndrome	0.000239	0.00382	CbGeAlD
Doxorubicin—RALBP1—bone marrow—acquired immunodeficiency syndrome	0.000238	0.00381	CbGeAlD
Doxorubicin—RALBP1—spinal cord—acquired immunodeficiency syndrome	0.000237	0.00379	CbGeAlD
Doxorubicin—NDUFS7—brain—acquired immunodeficiency syndrome	0.000237	0.00379	CbGeAlD
Doxorubicin—NOS2—Alpha9 beta1 integrin signaling events—CSF2—acquired immunodeficiency syndrome	0.000234	0.0256	CbGpPWpGaD
Doxorubicin—DHCR7—central nervous system—acquired immunodeficiency syndrome	0.000232	0.00371	CbGeAlD
Doxorubicin—CBR1—blood—acquired immunodeficiency syndrome	0.00023	0.00367	CbGeAlD
Doxorubicin—NDUFS7—lymph node—acquired immunodeficiency syndrome	0.000229	0.00366	CbGeAlD
Doxorubicin—RALBP1—vagina—acquired immunodeficiency syndrome	0.000228	0.00365	CbGeAlD
Doxorubicin—AKR1C3—blood—acquired immunodeficiency syndrome	0.000227	0.00363	CbGeAlD
Doxorubicin—NOS3—vagina—acquired immunodeficiency syndrome	0.000225	0.00359	CbGeAlD
Doxorubicin—CBR1—bone marrow—acquired immunodeficiency syndrome	0.000222	0.00355	CbGeAlD
Doxorubicin—CBR1—spinal cord—acquired immunodeficiency syndrome	0.000221	0.00354	CbGeAlD
Doxorubicin—YWHAG—nervous system—acquired immunodeficiency syndrome	0.000221	0.00354	CbGeAlD
Doxorubicin—AURKA—brain—acquired immunodeficiency syndrome	0.00022	0.00352	CbGeAlD
Doxorubicin—AKR1C3—bone marrow—acquired immunodeficiency syndrome	0.00022	0.00351	CbGeAlD
Doxorubicin—AKR1C3—spinal cord—acquired immunodeficiency syndrome	0.000219	0.0035	CbGeAlD
Doxorubicin—RALBP1—lung—acquired immunodeficiency syndrome	0.000216	0.00345	CbGeAlD
Doxorubicin—AURKA—Integrated Breast Cancer Pathway—APOBEC3G—acquired immunodeficiency syndrome	0.000214	0.0234	CbGpPWpGaD
Doxorubicin—YWHAG—central nervous system—acquired immunodeficiency syndrome	0.000213	0.00341	CbGeAlD
Doxorubicin—CBR1—vagina—acquired immunodeficiency syndrome	0.000213	0.00341	CbGeAlD
Doxorubicin—AURKA—lymph node—acquired immunodeficiency syndrome	0.000213	0.0034	CbGeAlD
Doxorubicin—NOS3—lung—acquired immunodeficiency syndrome	0.000212	0.00339	CbGeAlD
Doxorubicin—AKR1C3—vagina—acquired immunodeficiency syndrome	0.00021	0.00336	CbGeAlD
Doxorubicin—POR—blood—acquired immunodeficiency syndrome	0.000207	0.00331	CbGeAlD
Doxorubicin—CBR1—lung—acquired immunodeficiency syndrome	0.000201	0.00322	CbGeAlD
Doxorubicin—POR—bone marrow—acquired immunodeficiency syndrome	0.000201	0.00321	CbGeAlD
Doxorubicin—RALBP1—nervous system—acquired immunodeficiency syndrome	0.0002	0.00319	CbGeAlD
Doxorubicin—POR—spinal cord—acquired immunodeficiency syndrome	0.0002	0.00319	CbGeAlD
Doxorubicin—AKR1C3—lung—acquired immunodeficiency syndrome	0.000199	0.00318	CbGeAlD
Doxorubicin—NOS1—brain—acquired immunodeficiency syndrome	0.000198	0.00316	CbGeAlD
Doxorubicin—NOS3—nervous system—acquired immunodeficiency syndrome	0.000197	0.00314	CbGeAlD
Doxorubicin—NDUFS2—brain—acquired immunodeficiency syndrome	0.000196	0.00314	CbGeAlD
Doxorubicin—NDUFS3—brain—acquired immunodeficiency syndrome	0.000194	0.0031	CbGeAlD
Doxorubicin—NQO1—digestive system—acquired immunodeficiency syndrome	0.000193	0.00309	CbGeAlD
Doxorubicin—TOP2A—blood—acquired immunodeficiency syndrome	0.000193	0.00309	CbGeAlD
Doxorubicin—RALBP1—central nervous system—acquired immunodeficiency syndrome	0.000192	0.00308	CbGeAlD
Doxorubicin—POR—vagina—acquired immunodeficiency syndrome	0.000192	0.00307	CbGeAlD
Doxorubicin—NDUFS2—lymph node—acquired immunodeficiency syndrome	0.00019	0.00303	CbGeAlD
Doxorubicin—NOS3—central nervous system—acquired immunodeficiency syndrome	0.000189	0.00303	CbGeAlD
Doxorubicin—NDUFS3—lymph node—acquired immunodeficiency syndrome	0.000187	0.003	CbGeAlD
Doxorubicin—TOP2A—bone marrow—acquired immunodeficiency syndrome	0.000187	0.00299	CbGeAlD
Doxorubicin—CBR1—nervous system—acquired immunodeficiency syndrome	0.000187	0.00298	CbGeAlD
Doxorubicin—DHCR7—brain—acquired immunodeficiency syndrome	0.000184	0.00295	CbGeAlD
Doxorubicin—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.000183	0.00293	CbGeAlD
Doxorubicin—NOS2—IL12-mediated signaling events—CCL3—acquired immunodeficiency syndrome	0.000182	0.02	CbGpPWpGaD
Doxorubicin—POR—lung—acquired immunodeficiency syndrome	0.000182	0.0029	CbGeAlD
Doxorubicin—CYP2D6—blood plasma—acquired immunodeficiency syndrome	0.00018	0.00288	CbGeAlD
Doxorubicin—CBR1—central nervous system—acquired immunodeficiency syndrome	0.00018	0.00287	CbGeAlD
Doxorubicin—TOP2A—vagina—acquired immunodeficiency syndrome	0.000179	0.00286	CbGeAlD
Doxorubicin—DHCR7—lymph node—acquired immunodeficiency syndrome	0.000178	0.00285	CbGeAlD
Doxorubicin—NQO1—spinal cord—acquired immunodeficiency syndrome	0.000177	0.00284	CbGeAlD
Doxorubicin—ABCC10—lymphoid tissue—acquired immunodeficiency syndrome	0.000175	0.00279	CbGeAlD
Doxorubicin—ABCC3—digestive system—acquired immunodeficiency syndrome	0.000173	0.00277	CbGeAlD
Doxorubicin—ABCC10—digestive system—acquired immunodeficiency syndrome	0.000173	0.00276	CbGeAlD
Doxorubicin—NQO1—vagina—acquired immunodeficiency syndrome	0.000171	0.00273	CbGeAlD
Doxorubicin—CYP1B1—skin of body—acquired immunodeficiency syndrome	0.00017	0.00271	CbGeAlD
Doxorubicin—TOP2A—lung—acquired immunodeficiency syndrome	0.000169	0.00271	CbGeAlD
Doxorubicin—YWHAG—brain—acquired immunodeficiency syndrome	0.000169	0.0027	CbGeAlD
Doxorubicin—TOP2A—Circadian rythm related genes—CARTPT—acquired immunodeficiency syndrome	0.000167	0.0183	CbGpPWpGaD
Doxorubicin—NQO1—Amino acid and derivative metabolism—TAT—acquired immunodeficiency syndrome	0.000166	0.0182	CbGpPWpGaD
Doxorubicin—ABCC3—blood—acquired immunodeficiency syndrome	0.000165	0.00264	CbGeAlD
Doxorubicin—NOS2—Type II interferon signaling (IFNG)—HLA-B—acquired immunodeficiency syndrome	0.000165	0.018	CbGpPWpGaD
Doxorubicin—ABCC10—blood—acquired immunodeficiency syndrome	0.000164	0.00263	CbGeAlD
Doxorubicin—YWHAG—lymph node—acquired immunodeficiency syndrome	0.000163	0.00261	CbGeAlD
Doxorubicin—NQO1—lung—acquired immunodeficiency syndrome	0.000161	0.00258	CbGeAlD
Doxorubicin—ABCC10—bone marrow—acquired immunodeficiency syndrome	0.000159	0.00254	CbGeAlD
Doxorubicin—NOS1—Myometrial Relaxation and Contraction Pathways—ACTG1—acquired immunodeficiency syndrome	0.000159	0.0174	CbGpPWpGaD
Doxorubicin—ABCC10—spinal cord—acquired immunodeficiency syndrome	0.000158	0.00253	CbGeAlD
Doxorubicin—AURKA—Gemcitabine—Lamivudine—acquired immunodeficiency syndrome	0.000155	0.0755	CbGdCrCtD
Doxorubicin—RALBP1—brain—acquired immunodeficiency syndrome	0.000153	0.00244	CbGeAlD
Doxorubicin—ABCC10—vagina—acquired immunodeficiency syndrome	0.000152	0.00244	CbGeAlD
Doxorubicin—NOS3—brain—acquired immunodeficiency syndrome	0.00015	0.0024	CbGeAlD
Doxorubicin—NQO1—nervous system—acquired immunodeficiency syndrome	0.000149	0.00239	CbGeAlD
Doxorubicin—RALBP1—lymph node—acquired immunodeficiency syndrome	0.000148	0.00236	CbGeAlD
Doxorubicin—NOS3—lymph node—acquired immunodeficiency syndrome	0.000145	0.00232	CbGeAlD
Doxorubicin—ABCC3—lung—acquired immunodeficiency syndrome	0.000145	0.00232	CbGeAlD
Doxorubicin—ABCC10—lung—acquired immunodeficiency syndrome	0.000144	0.0023	CbGeAlD
Doxorubicin—NQO1—central nervous system—acquired immunodeficiency syndrome	0.000144	0.0023	CbGeAlD
Doxorubicin—NOS2—HIF-1-alpha transcription factor network—CXCL12—acquired immunodeficiency syndrome	0.000144	0.0157	CbGpPWpGaD
Doxorubicin—NOS2—HIF-1-alpha transcription factor network—CXCR4—acquired immunodeficiency syndrome	0.000144	0.0157	CbGpPWpGaD
Doxorubicin—CBR1—brain—acquired immunodeficiency syndrome	0.000143	0.00228	CbGeAlD
Doxorubicin—AURKA—Cytarabine—Lamivudine—acquired immunodeficiency syndrome	0.000142	0.0693	CbGdCrCtD
Doxorubicin—AKR1C3—brain—acquired immunodeficiency syndrome	0.000141	0.00225	CbGeAlD
Doxorubicin—ABCC2—digestive system—acquired immunodeficiency syndrome	0.000139	0.00222	CbGeAlD
Doxorubicin—CBR1—lymph node—acquired immunodeficiency syndrome	0.000138	0.0022	CbGeAlD
Doxorubicin—CYP1B1—lymphoid tissue—acquired immunodeficiency syndrome	0.000137	0.0022	CbGeAlD
Doxorubicin—ABCB11—Recycling of bile acids and salts—ALB—acquired immunodeficiency syndrome	0.000137	0.015	CbGpPWpGaD
Doxorubicin—AKR1C3—lymph node—acquired immunodeficiency syndrome	0.000136	0.00218	CbGeAlD
Doxorubicin—CYP1B1—digestive system—acquired immunodeficiency syndrome	0.000136	0.00217	CbGeAlD
Doxorubicin—ABCC3—nervous system—acquired immunodeficiency syndrome	0.000134	0.00214	CbGeAlD
Doxorubicin—ABCC2—blood—acquired immunodeficiency syndrome	0.000132	0.00211	CbGeAlD
Doxorubicin—ABCC3—Recycling of bile acids and salts—ALB—acquired immunodeficiency syndrome	0.000132	0.0144	CbGpPWpGaD
Doxorubicin—TOP2A—Cladribine—Abacavir—acquired immunodeficiency syndrome	0.000132	0.0641	CbGdCrCtD
Doxorubicin—ABCB1—blood plasma—acquired immunodeficiency syndrome	0.00013	0.00207	CbGeAlD
Doxorubicin—CYP1B1—blood—acquired immunodeficiency syndrome	0.000129	0.00207	CbGeAlD
Doxorubicin—ABCC3—central nervous system—acquired immunodeficiency syndrome	0.000129	0.00206	CbGeAlD
Doxorubicin—POR—brain—acquired immunodeficiency syndrome	0.000129	0.00206	CbGeAlD
Doxorubicin—NOS1—Spinal Cord Injury—CCR2—acquired immunodeficiency syndrome	0.000127	0.0139	CbGpPWpGaD
Doxorubicin—POR—lymph node—acquired immunodeficiency syndrome	0.000124	0.00199	CbGeAlD
Doxorubicin—TOP2A—Floxuridine—Zidovudine—acquired immunodeficiency syndrome	0.00012	0.0587	CbGdCrCtD
Doxorubicin—TOP2A—Floxuridine—Stavudine—acquired immunodeficiency syndrome	0.00012	0.0587	CbGdCrCtD
Doxorubicin—YWHAG—Myometrial Relaxation and Contraction Pathways—ACTG1—acquired immunodeficiency syndrome	0.000117	0.0128	CbGpPWpGaD
Doxorubicin—CYP2B6—skin of body—acquired immunodeficiency syndrome	0.000117	0.00186	CbGeAlD
Doxorubicin—ABCC1—blood—acquired immunodeficiency syndrome	0.000116	0.00186	CbGeAlD
Doxorubicin—NOS2—IL12-mediated signaling events—CD8A—acquired immunodeficiency syndrome	0.000116	0.0127	CbGpPWpGaD
Doxorubicin—TOP2A—lymph node—acquired immunodeficiency syndrome	0.000116	0.00185	CbGeAlD
Doxorubicin—NOS2—IL12-mediated signaling events—IL4—acquired immunodeficiency syndrome	0.000114	0.0125	CbGpPWpGaD
Doxorubicin—NQO1—brain—acquired immunodeficiency syndrome	0.000114	0.00183	CbGeAlD
Doxorubicin—CYP1B1—lung—acquired immunodeficiency syndrome	0.000113	0.00181	CbGeAlD
Doxorubicin—NQO1—lymph node—acquired immunodeficiency syndrome	0.00011	0.00176	CbGeAlD
Doxorubicin—ABCC1—vagina—acquired immunodeficiency syndrome	0.000108	0.00172	CbGeAlD
Doxorubicin—DHCR7—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	0.000107	0.0117	CbGpPWpGaD
Doxorubicin—NOS2—IL12-mediated signaling events—CCR5—acquired immunodeficiency syndrome	0.000106	0.0116	CbGpPWpGaD
Doxorubicin—CYP1B1—nervous system—acquired immunodeficiency syndrome	0.000105	0.00168	CbGeAlD
Doxorubicin—AKR1C3—Bile acid and bile salt metabolism—ALB—acquired immunodeficiency syndrome	0.000105	0.0115	CbGpPWpGaD
Doxorubicin—ABCC3—brain—acquired immunodeficiency syndrome	0.000103	0.00164	CbGeAlD
Doxorubicin—ABCC10—brain—acquired immunodeficiency syndrome	0.000102	0.00163	CbGeAlD
Doxorubicin—ABCC1—lung—acquired immunodeficiency syndrome	0.000102	0.00163	CbGeAlD
Doxorubicin—NOS2—Type II interferon signaling (IFNG)—IFNG—acquired immunodeficiency syndrome	0.000102	0.0111	CbGpPWpGaD
Doxorubicin—NOS2—IL23-mediated signaling events—IFNG—acquired immunodeficiency syndrome	0.000102	0.0111	CbGpPWpGaD
Doxorubicin—CYP1B1—central nervous system—acquired immunodeficiency syndrome	0.000101	0.00162	CbGeAlD
Doxorubicin—CBR1—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	9.97e-05	0.0109	CbGpPWpGaD
Doxorubicin—ABCC3—lymph node—acquired immunodeficiency syndrome	9.91e-05	0.00158	CbGeAlD
Doxorubicin—ABCC10—lymph node—acquired immunodeficiency syndrome	9.86e-05	0.00158	CbGeAlD
Doxorubicin—NOS2—IL23-mediated signaling events—CD4—acquired immunodeficiency syndrome	9.83e-05	0.0108	CbGpPWpGaD
Doxorubicin—NOS1—Monoamine Transport—TNF—acquired immunodeficiency syndrome	9.81e-05	0.0107	CbGpPWpGaD
Doxorubicin—ABCG2—blood—acquired immunodeficiency syndrome	9.63e-05	0.00154	CbGeAlD
Doxorubicin—NOS2—Spinal Cord Injury—CCR2—acquired immunodeficiency syndrome	9.61e-05	0.0105	CbGpPWpGaD
Doxorubicin—CYP2B6—lymphoid tissue—acquired immunodeficiency syndrome	9.44e-05	0.00151	CbGeAlD
Doxorubicin—CYP2B6—digestive system—acquired immunodeficiency syndrome	9.33e-05	0.00149	CbGeAlD
Doxorubicin—ABCG2—bone marrow—acquired immunodeficiency syndrome	9.32e-05	0.00149	CbGeAlD
Doxorubicin—NOS3—Myometrial Relaxation and Contraction Pathways—ACTG1—acquired immunodeficiency syndrome	9.31e-05	0.0102	CbGpPWpGaD
Doxorubicin—ABCG2—spinal cord—acquired immunodeficiency syndrome	9.28e-05	0.00148	CbGeAlD
Doxorubicin—NOS2—IL23-mediated signaling events—IL2—acquired immunodeficiency syndrome	9.05e-05	0.00991	CbGpPWpGaD
Doxorubicin—ABCG2—vagina—acquired immunodeficiency syndrome	8.93e-05	0.00143	CbGeAlD
Doxorubicin—CYP2B6—blood—acquired immunodeficiency syndrome	8.88e-05	0.00142	CbGeAlD
Doxorubicin—NOS1—Spinal Cord Injury—IL4—acquired immunodeficiency syndrome	8.83e-05	0.00967	CbGpPWpGaD
Doxorubicin—NOS1—Amyotrophic lateral sclerosis (ALS)—TNF—acquired immunodeficiency syndrome	8.55e-05	0.00936	CbGpPWpGaD
Doxorubicin—ABCG2—lung—acquired immunodeficiency syndrome	8.44e-05	0.00135	CbGeAlD
Doxorubicin—CYP2B6—vagina—acquired immunodeficiency syndrome	8.24e-05	0.00132	CbGeAlD
Doxorubicin—NQO1—Aryl Hydrocarbon Receptor Pathway—IFNG—acquired immunodeficiency syndrome	8.15e-05	0.00892	CbGpPWpGaD
Doxorubicin—CYP1B1—brain—acquired immunodeficiency syndrome	8.02e-05	0.00128	CbGeAlD
Doxorubicin—ABCC2—lymph node—acquired immunodeficiency syndrome	7.92e-05	0.00127	CbGeAlD
Doxorubicin—CYP2B6—lung—acquired immunodeficiency syndrome	7.79e-05	0.00124	CbGeAlD
Doxorubicin—CYP1B1—lymph node—acquired immunodeficiency syndrome	7.75e-05	0.00124	CbGeAlD
Doxorubicin—NQO1—Aryl Hydrocarbon Receptor Pathway—IL2—acquired immunodeficiency syndrome	7.24e-05	0.00793	CbGpPWpGaD
Doxorubicin—ABCC1—brain—acquired immunodeficiency syndrome	7.22e-05	0.00115	CbGeAlD
Doxorubicin—CYP2B6—nervous system—acquired immunodeficiency syndrome	7.21e-05	0.00115	CbGeAlD
Doxorubicin—ABCB11—Bile acid and bile salt metabolism—ALB—acquired immunodeficiency syndrome	7.18e-05	0.00786	CbGpPWpGaD
Doxorubicin—ABCB1—retina—acquired immunodeficiency syndrome	7.1e-05	0.00113	CbGeAlD
Doxorubicin—CYP3A4—digestive system—acquired immunodeficiency syndrome	7.04e-05	0.00113	CbGeAlD
Doxorubicin—NOS2—ATF-2 transcription factor network—IFNG—acquired immunodeficiency syndrome	7.01e-05	0.00767	CbGpPWpGaD
Doxorubicin—NDUFS3—Metabolism—TAT—acquired immunodeficiency syndrome	7e-05	0.00767	CbGpPWpGaD
Doxorubicin—NDUFS7—Metabolism—TAT—acquired immunodeficiency syndrome	7e-05	0.00767	CbGpPWpGaD
Doxorubicin—ABCC1—lymph node—acquired immunodeficiency syndrome	6.97e-05	0.00111	CbGeAlD
Doxorubicin—CYP2B6—central nervous system—acquired immunodeficiency syndrome	6.94e-05	0.00111	CbGeAlD
Doxorubicin—CYP2D6—digestive system—acquired immunodeficiency syndrome	6.93e-05	0.00111	CbGeAlD
Doxorubicin—NOS2—IL12-mediated signaling events—IFNG—acquired immunodeficiency syndrome	6.92e-05	0.00757	CbGpPWpGaD
Doxorubicin—ABCC3—Bile acid and bile salt metabolism—ALB—acquired immunodeficiency syndrome	6.89e-05	0.00754	CbGpPWpGaD
Doxorubicin—CYP3A4—blood—acquired immunodeficiency syndrome	6.71e-05	0.00107	CbGeAlD
Doxorubicin—NOS2—IL12-mediated signaling events—CD4—acquired immunodeficiency syndrome	6.68e-05	0.00731	CbGpPWpGaD
Doxorubicin—NOS2—Spinal Cord Injury—IL4—acquired immunodeficiency syndrome	6.66e-05	0.00729	CbGpPWpGaD
Doxorubicin—CYP2D6—blood—acquired immunodeficiency syndrome	6.6e-05	0.00106	CbGeAlD
Doxorubicin—NOS2—IL23-mediated signaling events—TNF—acquired immunodeficiency syndrome	6.59e-05	0.00721	CbGpPWpGaD
Doxorubicin—NDUFS2—Metabolism—TAT—acquired immunodeficiency syndrome	6.58e-05	0.00721	CbGpPWpGaD
Doxorubicin—NOS2—IL12-mediated signaling events—IL2—acquired immunodeficiency syndrome	6.14e-05	0.00673	CbGpPWpGaD
Doxorubicin—ABCG2—HIF-1-alpha transcription factor network—CXCR4—acquired immunodeficiency syndrome	5.99e-05	0.00655	CbGpPWpGaD
Doxorubicin—ABCG2—HIF-1-alpha transcription factor network—CXCL12—acquired immunodeficiency syndrome	5.99e-05	0.00655	CbGpPWpGaD
Doxorubicin—ABCG2—brain—acquired immunodeficiency syndrome	5.98e-05	0.000955	CbGeAlD
Doxorubicin—NDUFS7—Metabolism—AGPS—acquired immunodeficiency syndrome	5.95e-05	0.00652	CbGpPWpGaD
Doxorubicin—NDUFS3—Metabolism—AGPS—acquired immunodeficiency syndrome	5.95e-05	0.00652	CbGpPWpGaD
Doxorubicin—TOP2A—Gemcitabine—Lamivudine—acquired immunodeficiency syndrome	5.92e-05	0.0288	CbGdCrCtD
Doxorubicin—ABCG2—lymph node—acquired immunodeficiency syndrome	5.77e-05	0.000923	CbGeAlD
Doxorubicin—AKR1C3—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	5.61e-05	0.00615	CbGpPWpGaD
Doxorubicin—NDUFS2—Metabolism—AGPS—acquired immunodeficiency syndrome	5.6e-05	0.00613	CbGpPWpGaD
Doxorubicin—DHCR7—Metabolism—TAT—acquired immunodeficiency syndrome	5.6e-05	0.00613	CbGpPWpGaD
Doxorubicin—SLC22A16—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	5.52e-05	0.00604	CbGpPWpGaD
Doxorubicin—NOS3—SHP2 signaling—IFNG—acquired immunodeficiency syndrome	5.52e-05	0.00604	CbGpPWpGaD
Doxorubicin—CYP2B6—brain—acquired immunodeficiency syndrome	5.51e-05	0.000881	CbGeAlD
Doxorubicin—CYP3A4—nervous system—acquired immunodeficiency syndrome	5.45e-05	0.000871	CbGeAlD
Doxorubicin—TOP2A—Cytarabine—Lamivudine—acquired immunodeficiency syndrome	5.44e-05	0.0265	CbGdCrCtD
Doxorubicin—CYP2D6—nervous system—acquired immunodeficiency syndrome	5.36e-05	0.000857	CbGeAlD
Doxorubicin—YWHAG—SIDS Susceptibility Pathways—IL10—acquired immunodeficiency syndrome	5.35e-05	0.00586	CbGpPWpGaD
Doxorubicin—NOS1—Spinal Cord Injury—IFNG—acquired immunodeficiency syndrome	5.34e-05	0.00584	CbGpPWpGaD
Doxorubicin—NOS2—IL23-mediated signaling events—IL6—acquired immunodeficiency syndrome	5.32e-05	0.00582	CbGpPWpGaD
Doxorubicin—NQO1—Aryl Hydrocarbon Receptor—TNF—acquired immunodeficiency syndrome	5.27e-05	0.00577	CbGpPWpGaD
Doxorubicin—NQO1—Aryl Hydrocarbon Receptor Pathway—TNF—acquired immunodeficiency syndrome	5.27e-05	0.00577	CbGpPWpGaD
Doxorubicin—CYP3A4—central nervous system—acquired immunodeficiency syndrome	5.24e-05	0.000838	CbGeAlD
Doxorubicin—CBR1—Metabolism—TAT—acquired immunodeficiency syndrome	5.22e-05	0.00572	CbGpPWpGaD
Doxorubicin—CYP2D6—central nervous system—acquired immunodeficiency syndrome	5.16e-05	0.000825	CbGeAlD
Doxorubicin—ABCB1—lymphoid tissue—acquired immunodeficiency syndrome	5.05e-05	0.000807	CbGeAlD
Doxorubicin—ABCB1—digestive system—acquired immunodeficiency syndrome	4.98e-05	0.000797	CbGeAlD
Doxorubicin—RALBP1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	4.98e-05	0.00545	CbGpPWpGaD
Doxorubicin—NOS3—SHP2 signaling—IL2—acquired immunodeficiency syndrome	4.9e-05	0.00537	CbGpPWpGaD
Doxorubicin—XDH—Selenium Micronutrient Network—ALB—acquired immunodeficiency syndrome	4.77e-05	0.00522	CbGpPWpGaD
Doxorubicin—NOS1—Alzheimers Disease—TNF—acquired immunodeficiency syndrome	4.76e-05	0.00521	CbGpPWpGaD
Doxorubicin—DHCR7—Metabolism—AGPS—acquired immunodeficiency syndrome	4.76e-05	0.00521	CbGpPWpGaD
Doxorubicin—ABCB1—blood—acquired immunodeficiency syndrome	4.75e-05	0.000759	CbGeAlD
Doxorubicin—NOS1—Spinal Cord Injury—IL2—acquired immunodeficiency syndrome	4.74e-05	0.00519	CbGpPWpGaD
Doxorubicin—NQO1—Apoptosis-related network due to altered Notch3 in ovarian cancer—TNF—acquired immunodeficiency syndrome	4.71e-05	0.00515	CbGpPWpGaD
Doxorubicin—ABCB1—bone marrow—acquired immunodeficiency syndrome	4.59e-05	0.000734	CbGeAlD
Doxorubicin—ABCB1—spinal cord—acquired immunodeficiency syndrome	4.58e-05	0.000731	CbGeAlD
Doxorubicin—ABCB8—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	4.54e-05	0.00497	CbGpPWpGaD
Doxorubicin—CBR1—Metabolism—AGPS—acquired immunodeficiency syndrome	4.44e-05	0.00486	CbGpPWpGaD
Doxorubicin—ABCB1—vagina—acquired immunodeficiency syndrome	4.4e-05	0.000704	CbGeAlD
Doxorubicin—XDH—Selenium Micronutrient Network—IFNG—acquired immunodeficiency syndrome	4.35e-05	0.00476	CbGpPWpGaD
Doxorubicin—ABCB1—lung—acquired immunodeficiency syndrome	4.16e-05	0.000665	CbGeAlD
Doxorubicin—NOS3—Validated transcriptional targets of AP1 family members Fra1 and Fra2—IL6—acquired immunodeficiency syndrome	4.13e-05	0.00452	CbGpPWpGaD
Doxorubicin—CYP2D6—brain—acquired immunodeficiency syndrome	4.1e-05	0.000655	CbGeAlD
Doxorubicin—NOS1—Disease—APOBEC3G—acquired immunodeficiency syndrome	4.05e-05	0.00443	CbGpPWpGaD
Doxorubicin—NOS2—Spinal Cord Injury—IFNG—acquired immunodeficiency syndrome	4.03e-05	0.00441	CbGpPWpGaD
Doxorubicin—NOS3—Angiopoietin receptor Tie2-mediated signaling—TNF—acquired immunodeficiency syndrome	4.02e-05	0.0044	CbGpPWpGaD
Doxorubicin—CYP1B1—Aryl Hydrocarbon Receptor Pathway—IFNG—acquired immunodeficiency syndrome	3.91e-05	0.00429	CbGpPWpGaD
Doxorubicin—ABCB1—nervous system—acquired immunodeficiency syndrome	3.86e-05	0.000616	CbGeAlD
Doxorubicin—ABCB11—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	3.85e-05	0.00421	CbGpPWpGaD
Doxorubicin—ABCB1—central nervous system—acquired immunodeficiency syndrome	3.71e-05	0.000593	CbGeAlD
Doxorubicin—ABCC3—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	3.69e-05	0.00404	CbGpPWpGaD
Doxorubicin—NOS2—ATF-2 transcription factor network—IL6—acquired immunodeficiency syndrome	3.66e-05	0.00401	CbGpPWpGaD
Doxorubicin—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	3.58e-05	0.000258	CcSEcCtD
Doxorubicin—NOS1—Hemostasis—IFNA1—acquired immunodeficiency syndrome	3.58e-05	0.00392	CbGpPWpGaD
Doxorubicin—NOS2—Spinal Cord Injury—IL2—acquired immunodeficiency syndrome	3.58e-05	0.00392	CbGpPWpGaD
Doxorubicin—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	3.58e-05	0.000258	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	3.57e-05	0.000257	CcSEcCtD
Doxorubicin—Pruritus—Abacavir—acquired immunodeficiency syndrome	3.56e-05	0.000257	CcSEcCtD
Doxorubicin—Fatigue—Indinavir—acquired immunodeficiency syndrome	3.56e-05	0.000257	CcSEcCtD
Doxorubicin—Anorexia—Delavirdine—acquired immunodeficiency syndrome	3.56e-05	0.000257	CcSEcCtD
Doxorubicin—Discomfort—Ritonavir—acquired immunodeficiency syndrome	3.56e-05	0.000257	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	3.56e-05	0.000257	CcSEcCtD
Doxorubicin—Cough—Saquinavir—acquired immunodeficiency syndrome	3.55e-05	0.000257	CcSEcCtD
Doxorubicin—Pain—Indinavir—acquired immunodeficiency syndrome	3.53e-05	0.000255	CcSEcCtD
Doxorubicin—Constipation—Indinavir—acquired immunodeficiency syndrome	3.53e-05	0.000255	CcSEcCtD
Doxorubicin—Insomnia—Efavirenz—acquired immunodeficiency syndrome	3.53e-05	0.000255	CcSEcCtD
Doxorubicin—Urticaria—Zidovudine—acquired immunodeficiency syndrome	3.53e-05	0.000255	CcSEcCtD
Doxorubicin—Convulsion—Saquinavir—acquired immunodeficiency syndrome	3.53e-05	0.000255	CcSEcCtD
Doxorubicin—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	3.52e-05	0.000254	CcSEcCtD
Doxorubicin—Hypertension—Saquinavir—acquired immunodeficiency syndrome	3.52e-05	0.000254	CcSEcCtD
Doxorubicin—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	3.51e-05	0.000253	CcSEcCtD
Doxorubicin—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	3.51e-05	0.000253	CcSEcCtD
Doxorubicin—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	3.51e-05	0.000253	CcSEcCtD
Doxorubicin—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	3.5e-05	0.000253	CcSEcCtD
Doxorubicin—Malaise—Lamivudine—acquired immunodeficiency syndrome	3.5e-05	0.000253	CcSEcCtD
Doxorubicin—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	3.5e-05	0.000252	CcSEcCtD
Doxorubicin—Nausea—Didanosine—acquired immunodeficiency syndrome	3.5e-05	0.000252	CcSEcCtD
Doxorubicin—Vertigo—Lamivudine—acquired immunodeficiency syndrome	3.49e-05	0.000252	CcSEcCtD
Doxorubicin—Hypotension—Delavirdine—acquired immunodeficiency syndrome	3.49e-05	0.000252	CcSEcCtD
Doxorubicin—Syncope—Lamivudine—acquired immunodeficiency syndrome	3.48e-05	0.000252	CcSEcCtD
Doxorubicin—Confusional state—Ritonavir—acquired immunodeficiency syndrome	3.48e-05	0.000251	CcSEcCtD
Doxorubicin—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	3.48e-05	0.000251	CcSEcCtD
Doxorubicin—CYP1B1—Aryl Hydrocarbon Receptor Pathway—IL2—acquired immunodeficiency syndrome	3.48e-05	0.00381	CbGpPWpGaD
Doxorubicin—Leukopenia—Lamivudine—acquired immunodeficiency syndrome	3.48e-05	0.000251	CcSEcCtD
Doxorubicin—Somnolence—Efavirenz—acquired immunodeficiency syndrome	3.47e-05	0.00025	CcSEcCtD
Doxorubicin—Chest pain—Saquinavir—acquired immunodeficiency syndrome	3.47e-05	0.00025	CcSEcCtD
Doxorubicin—Myalgia—Saquinavir—acquired immunodeficiency syndrome	3.47e-05	0.00025	CcSEcCtD
Doxorubicin—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	3.47e-05	0.00025	CcSEcCtD
Doxorubicin—Anxiety—Saquinavir—acquired immunodeficiency syndrome	3.45e-05	0.000249	CcSEcCtD
Doxorubicin—NOS1—Spinal Cord Injury—TNF—acquired immunodeficiency syndrome	3.45e-05	0.00378	CbGpPWpGaD
Doxorubicin—Oedema—Ritonavir—acquired immunodeficiency syndrome	3.45e-05	0.000249	CcSEcCtD
Doxorubicin—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	3.44e-05	0.000249	CcSEcCtD
Doxorubicin—NOS1—Disease—CCNT1—acquired immunodeficiency syndrome	3.44e-05	0.00377	CbGpPWpGaD
Doxorubicin—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	3.44e-05	0.000249	CcSEcCtD
Doxorubicin—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	3.44e-05	0.000248	CcSEcCtD
Doxorubicin—Discomfort—Saquinavir—acquired immunodeficiency syndrome	3.43e-05	0.000247	CcSEcCtD
Doxorubicin—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	3.41e-05	0.000247	CcSEcCtD
Doxorubicin—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	3.4e-05	0.000246	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	3.4e-05	0.000246	CcSEcCtD
Doxorubicin—Shock—Ritonavir—acquired immunodeficiency syndrome	3.4e-05	0.000245	CcSEcCtD
Doxorubicin—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	3.39e-05	0.000245	CcSEcCtD
Doxorubicin—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	3.39e-05	0.000245	CcSEcCtD
Doxorubicin—Cough—Lamivudine—acquired immunodeficiency syndrome	3.39e-05	0.000245	CcSEcCtD
Doxorubicin—NOS3—Corticotropin-releasing hormone—IL2—acquired immunodeficiency syndrome	3.39e-05	0.00371	CbGpPWpGaD
Doxorubicin—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	3.39e-05	0.000245	CcSEcCtD
Doxorubicin—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	3.39e-05	0.000244	CcSEcCtD
Doxorubicin—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	3.38e-05	0.000244	CcSEcCtD
Doxorubicin—Dizziness—Stavudine—acquired immunodeficiency syndrome	3.38e-05	0.000244	CcSEcCtD
Doxorubicin—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	3.38e-05	0.000244	CcSEcCtD
Doxorubicin—Insomnia—Delavirdine—acquired immunodeficiency syndrome	3.38e-05	0.000244	CcSEcCtD
Doxorubicin—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	3.37e-05	0.000243	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	3.37e-05	0.000243	CcSEcCtD
Doxorubicin—Convulsion—Lamivudine—acquired immunodeficiency syndrome	3.37e-05	0.000243	CcSEcCtD
Doxorubicin—Vomiting—Nevirapine—acquired immunodeficiency syndrome	3.36e-05	0.000243	CcSEcCtD
Doxorubicin—Fatigue—Efavirenz—acquired immunodeficiency syndrome	3.36e-05	0.000243	CcSEcCtD
Doxorubicin—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	3.35e-05	0.000242	CcSEcCtD
Doxorubicin—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	3.35e-05	0.000242	CcSEcCtD
Doxorubicin—Confusional state—Saquinavir—acquired immunodeficiency syndrome	3.35e-05	0.000242	CcSEcCtD
Doxorubicin—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	3.34e-05	0.000241	CcSEcCtD
Doxorubicin—Pain—Efavirenz—acquired immunodeficiency syndrome	3.34e-05	0.000241	CcSEcCtD
Doxorubicin—Constipation—Efavirenz—acquired immunodeficiency syndrome	3.34e-05	0.000241	CcSEcCtD
Doxorubicin—Rash—Nevirapine—acquired immunodeficiency syndrome	3.34e-05	0.000241	CcSEcCtD
Doxorubicin—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	3.33e-05	0.000241	CcSEcCtD
Doxorubicin—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	3.33e-05	0.00024	CcSEcCtD
Doxorubicin—Dizziness—Abacavir—acquired immunodeficiency syndrome	3.33e-05	0.00024	CcSEcCtD
Doxorubicin—Oedema—Saquinavir—acquired immunodeficiency syndrome	3.32e-05	0.00024	CcSEcCtD
Doxorubicin—Somnolence—Delavirdine—acquired immunodeficiency syndrome	3.32e-05	0.00024	CcSEcCtD
Doxorubicin—Headache—Nevirapine—acquired immunodeficiency syndrome	3.32e-05	0.000239	CcSEcCtD
Doxorubicin—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	3.31e-05	0.000239	CcSEcCtD
Doxorubicin—Myalgia—Lamivudine—acquired immunodeficiency syndrome	3.31e-05	0.000239	CcSEcCtD
Doxorubicin—Chest pain—Lamivudine—acquired immunodeficiency syndrome	3.31e-05	0.000239	CcSEcCtD
Doxorubicin—Infection—Saquinavir—acquired immunodeficiency syndrome	3.3e-05	0.000238	CcSEcCtD
Doxorubicin—Anxiety—Lamivudine—acquired immunodeficiency syndrome	3.3e-05	0.000238	CcSEcCtD
Doxorubicin—Anorexia—Ritonavir—acquired immunodeficiency syndrome	3.29e-05	0.000238	CcSEcCtD
Doxorubicin—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	3.29e-05	0.000237	CcSEcCtD
Doxorubicin—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	3.28e-05	0.000237	CcSEcCtD
Doxorubicin—Urticaria—Indinavir—acquired immunodeficiency syndrome	3.28e-05	0.000237	CcSEcCtD
Doxorubicin—Shock—Saquinavir—acquired immunodeficiency syndrome	3.27e-05	0.000236	CcSEcCtD
Doxorubicin—Discomfort—Lamivudine—acquired immunodeficiency syndrome	3.27e-05	0.000236	CcSEcCtD
Doxorubicin—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	3.27e-05	0.000236	CcSEcCtD
Doxorubicin—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	3.27e-05	0.000236	CcSEcCtD
Doxorubicin—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	3.26e-05	0.000235	CcSEcCtD
Doxorubicin—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	3.26e-05	0.000235	CcSEcCtD
Doxorubicin—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	3.25e-05	0.000235	CcSEcCtD
Doxorubicin—Vomiting—Stavudine—acquired immunodeficiency syndrome	3.25e-05	0.000235	CcSEcCtD
Doxorubicin—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	3.25e-05	0.000234	CcSEcCtD
Doxorubicin—ABCB1—HIF-1-alpha transcription factor network—CXCR4—acquired immunodeficiency syndrome	3.24e-05	0.00354	CbGpPWpGaD
Doxorubicin—ABCB1—HIF-1-alpha transcription factor network—CXCL12—acquired immunodeficiency syndrome	3.24e-05	0.00354	CbGpPWpGaD
Doxorubicin—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	3.23e-05	0.000234	CcSEcCtD
Doxorubicin—Rash—Nelfinavir—acquired immunodeficiency syndrome	3.23e-05	0.000233	CcSEcCtD
Doxorubicin—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	3.23e-05	0.000233	CcSEcCtD
Doxorubicin—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	3.23e-05	0.000233	CcSEcCtD
Doxorubicin—Hypotension—Ritonavir—acquired immunodeficiency syndrome	3.23e-05	0.000233	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	3.22e-05	0.000233	CcSEcCtD
Doxorubicin—Rash—Stavudine—acquired immunodeficiency syndrome	3.22e-05	0.000233	CcSEcCtD
Doxorubicin—Fatigue—Delavirdine—acquired immunodeficiency syndrome	3.22e-05	0.000232	CcSEcCtD
Doxorubicin—Dermatitis—Stavudine—acquired immunodeficiency syndrome	3.22e-05	0.000232	CcSEcCtD
Doxorubicin—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	3.22e-05	0.000232	CcSEcCtD
Doxorubicin—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	3.21e-05	0.000232	CcSEcCtD
Doxorubicin—Headache—Nelfinavir—acquired immunodeficiency syndrome	3.21e-05	0.000232	CcSEcCtD
Doxorubicin—Headache—Stavudine—acquired immunodeficiency syndrome	3.2e-05	0.000231	CcSEcCtD
Doxorubicin—Vomiting—Abacavir—acquired immunodeficiency syndrome	3.2e-05	0.000231	CcSEcCtD
Doxorubicin—Confusional state—Lamivudine—acquired immunodeficiency syndrome	3.2e-05	0.000231	CcSEcCtD
Doxorubicin—Pain—Delavirdine—acquired immunodeficiency syndrome	3.19e-05	0.000231	CcSEcCtD
Doxorubicin—Constipation—Delavirdine—acquired immunodeficiency syndrome	3.19e-05	0.000231	CcSEcCtD
Doxorubicin—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	3.19e-05	0.00023	CcSEcCtD
Doxorubicin—Asthenia—Zidovudine—acquired immunodeficiency syndrome	3.19e-05	0.00023	CcSEcCtD
Doxorubicin—Rash—Abacavir—acquired immunodeficiency syndrome	3.17e-05	0.000229	CcSEcCtD
Doxorubicin—Dermatitis—Abacavir—acquired immunodeficiency syndrome	3.17e-05	0.000229	CcSEcCtD
Doxorubicin—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	3.17e-05	0.000229	CcSEcCtD
Doxorubicin—Oedema—Lamivudine—acquired immunodeficiency syndrome	3.17e-05	0.000229	CcSEcCtD
Doxorubicin—Anorexia—Saquinavir—acquired immunodeficiency syndrome	3.17e-05	0.000229	CcSEcCtD
Doxorubicin—Headache—Abacavir—acquired immunodeficiency syndrome	3.15e-05	0.000228	CcSEcCtD
Doxorubicin—Infection—Lamivudine—acquired immunodeficiency syndrome	3.15e-05	0.000227	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	3.15e-05	0.000227	CcSEcCtD
Doxorubicin—Nausea—Nevirapine—acquired immunodeficiency syndrome	3.14e-05	0.000227	CcSEcCtD
Doxorubicin—Pruritus—Zidovudine—acquired immunodeficiency syndrome	3.14e-05	0.000227	CcSEcCtD
Doxorubicin—Insomnia—Ritonavir—acquired immunodeficiency syndrome	3.12e-05	0.000225	CcSEcCtD
Doxorubicin—Shock—Lamivudine—acquired immunodeficiency syndrome	3.12e-05	0.000225	CcSEcCtD
Doxorubicin—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	3.11e-05	0.000224	CcSEcCtD
Doxorubicin—Hypotension—Saquinavir—acquired immunodeficiency syndrome	3.11e-05	0.000224	CcSEcCtD
Doxorubicin—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	3.1e-05	0.000224	CcSEcCtD
Doxorubicin—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	3.1e-05	0.000224	CcSEcCtD
Doxorubicin—Urticaria—Efavirenz—acquired immunodeficiency syndrome	3.1e-05	0.000224	CcSEcCtD
Doxorubicin—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	3.08e-05	0.000223	CcSEcCtD
Doxorubicin—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	3.08e-05	0.000223	CcSEcCtD
Doxorubicin—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	3.08e-05	0.000222	CcSEcCtD
Doxorubicin—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	3.08e-05	0.000222	CcSEcCtD
Doxorubicin—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	3.08e-05	0.000222	CcSEcCtD
Doxorubicin—Somnolence—Ritonavir—acquired immunodeficiency syndrome	3.07e-05	0.000222	CcSEcCtD
Doxorubicin—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	3.06e-05	0.000221	CcSEcCtD
Doxorubicin—NOS2—Disease—APOBEC3G—acquired immunodeficiency syndrome	3.05e-05	0.00335	CbGpPWpGaD
Doxorubicin—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	3.05e-05	0.00022	CcSEcCtD
Doxorubicin—NQO1—Metabolism—TAT—acquired immunodeficiency syndrome	3.05e-05	0.00334	CbGpPWpGaD
Doxorubicin—Nausea—Nelfinavir—acquired immunodeficiency syndrome	3.04e-05	0.00022	CcSEcCtD
Doxorubicin—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	3.04e-05	0.00022	CcSEcCtD
Doxorubicin—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	3.04e-05	0.000219	CcSEcCtD
Doxorubicin—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	3.04e-05	0.000219	CcSEcCtD
Doxorubicin—Nausea—Stavudine—acquired immunodeficiency syndrome	3.04e-05	0.000219	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	3.03e-05	0.000219	CcSEcCtD
Doxorubicin—Anorexia—Lamivudine—acquired immunodeficiency syndrome	3.02e-05	0.000218	CcSEcCtD
Doxorubicin—RALBP1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	3.02e-05	0.0033	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	3.02e-05	0.0033	CbGpPWpGaD
Doxorubicin—Insomnia—Saquinavir—acquired immunodeficiency syndrome	3.01e-05	0.000217	CcSEcCtD
Doxorubicin—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	3e-05	0.000217	CcSEcCtD
Doxorubicin—Nausea—Abacavir—acquired immunodeficiency syndrome	2.99e-05	0.000216	CcSEcCtD
Doxorubicin—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	2.98e-05	0.000215	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	2.98e-05	0.000215	CcSEcCtD
Doxorubicin—Fatigue—Ritonavir—acquired immunodeficiency syndrome	2.98e-05	0.000215	CcSEcCtD
Doxorubicin—Urticaria—Delavirdine—acquired immunodeficiency syndrome	2.97e-05	0.000214	CcSEcCtD
Doxorubicin—Asthenia—Indinavir—acquired immunodeficiency syndrome	2.96e-05	0.000214	CcSEcCtD
Doxorubicin—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	2.96e-05	0.000214	CcSEcCtD
Doxorubicin—Hypotension—Lamivudine—acquired immunodeficiency syndrome	2.96e-05	0.000214	CcSEcCtD
Doxorubicin—Somnolence—Saquinavir—acquired immunodeficiency syndrome	2.95e-05	0.000213	CcSEcCtD
Doxorubicin—Constipation—Ritonavir—acquired immunodeficiency syndrome	2.95e-05	0.000213	CcSEcCtD
Doxorubicin—Pain—Ritonavir—acquired immunodeficiency syndrome	2.95e-05	0.000213	CcSEcCtD
Doxorubicin—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	2.95e-05	0.000213	CcSEcCtD
Doxorubicin—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	2.95e-05	0.000213	CcSEcCtD
Doxorubicin—ABCB1—brain—acquired immunodeficiency syndrome	2.95e-05	0.000471	CbGeAlD
Doxorubicin—AKR1C3—Metabolism—TAT—acquired immunodeficiency syndrome	2.94e-05	0.00322	CbGpPWpGaD
Doxorubicin—Dizziness—Zidovudine—acquired immunodeficiency syndrome	2.94e-05	0.000212	CcSEcCtD
Doxorubicin—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	2.93e-05	0.000211	CcSEcCtD
Doxorubicin—Pruritus—Indinavir—acquired immunodeficiency syndrome	2.92e-05	0.000211	CcSEcCtD
Doxorubicin—ABCC1—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	2.89e-05	0.00317	CbGpPWpGaD
Doxorubicin—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	2.89e-05	0.000209	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	2.89e-05	0.000209	CcSEcCtD
Doxorubicin—NOS3—SHP2 signaling—IL6—acquired immunodeficiency syndrome	2.88e-05	0.00316	CbGpPWpGaD
Doxorubicin—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	2.88e-05	0.000208	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	2.87e-05	0.000207	CcSEcCtD
Doxorubicin—Insomnia—Lamivudine—acquired immunodeficiency syndrome	2.87e-05	0.000207	CcSEcCtD
Doxorubicin—Fatigue—Saquinavir—acquired immunodeficiency syndrome	2.87e-05	0.000207	CcSEcCtD
Doxorubicin—ABCB1—lymph node—acquired immunodeficiency syndrome	2.85e-05	0.000455	CbGeAlD
Doxorubicin—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	2.85e-05	0.000206	CcSEcCtD
Doxorubicin—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	2.85e-05	0.000205	CcSEcCtD
Doxorubicin—Pain—Saquinavir—acquired immunodeficiency syndrome	2.84e-05	0.000205	CcSEcCtD
Doxorubicin—Constipation—Saquinavir—acquired immunodeficiency syndrome	2.84e-05	0.000205	CcSEcCtD
Doxorubicin—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	2.83e-05	0.000204	CcSEcCtD
Doxorubicin—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	2.83e-05	0.000204	CcSEcCtD
Doxorubicin—Vomiting—Zidovudine—acquired immunodeficiency syndrome	2.82e-05	0.000204	CcSEcCtD
Doxorubicin—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	2.82e-05	0.000204	CcSEcCtD
Doxorubicin—Somnolence—Lamivudine—acquired immunodeficiency syndrome	2.82e-05	0.000203	CcSEcCtD
Doxorubicin—XDH—Selenium Micronutrient Network—TNF—acquired immunodeficiency syndrome	2.81e-05	0.00308	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—APOBEC3G—acquired immunodeficiency syndrome	2.81e-05	0.00307	CbGpPWpGaD
Doxorubicin—SLC22A16—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	2.8e-05	0.00307	CbGpPWpGaD
Doxorubicin—ABCB1—Allograft Rejection—CXCL12—acquired immunodeficiency syndrome	2.8e-05	0.00307	CbGpPWpGaD
Doxorubicin—Rash—Zidovudine—acquired immunodeficiency syndrome	2.8e-05	0.000202	CcSEcCtD
Doxorubicin—NOS1—Hemostasis—CSF2—acquired immunodeficiency syndrome	2.8e-05	0.00307	CbGpPWpGaD
Doxorubicin—Asthenia—Efavirenz—acquired immunodeficiency syndrome	2.8e-05	0.000202	CcSEcCtD
Doxorubicin—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	2.8e-05	0.000202	CcSEcCtD
Doxorubicin—CYP1B1—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	2.8e-05	0.00306	CbGpPWpGaD
Doxorubicin—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	2.79e-05	0.000201	CcSEcCtD
Doxorubicin—NOS1—Spinal Cord Injury—IL6—acquired immunodeficiency syndrome	2.79e-05	0.00305	CbGpPWpGaD
Doxorubicin—Headache—Zidovudine—acquired immunodeficiency syndrome	2.78e-05	0.000201	CcSEcCtD
Doxorubicin—Pruritus—Efavirenz—acquired immunodeficiency syndrome	2.76e-05	0.000199	CcSEcCtD
Doxorubicin—AKR1C3—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	2.76e-05	0.00302	CbGpPWpGaD
Doxorubicin—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	2.76e-05	0.000199	CcSEcCtD
Doxorubicin—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	2.75e-05	0.000199	CcSEcCtD
Doxorubicin—Urticaria—Ritonavir—acquired immunodeficiency syndrome	2.74e-05	0.000198	CcSEcCtD
Doxorubicin—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	2.74e-05	0.000198	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	2.74e-05	0.000198	CcSEcCtD
Doxorubicin—XDH—Metabolism—TAT—acquired immunodeficiency syndrome	2.73e-05	0.00299	CbGpPWpGaD
Doxorubicin—Fatigue—Lamivudine—acquired immunodeficiency syndrome	2.73e-05	0.000197	CcSEcCtD
Doxorubicin—Dizziness—Indinavir—acquired immunodeficiency syndrome	2.73e-05	0.000197	CcSEcCtD
Doxorubicin—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	2.73e-05	0.000197	CcSEcCtD
Doxorubicin—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	2.73e-05	0.000197	CcSEcCtD
Doxorubicin—RALBP1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	2.73e-05	0.00299	CbGpPWpGaD
Doxorubicin—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	2.72e-05	0.000196	CcSEcCtD
Doxorubicin—Pain—Lamivudine—acquired immunodeficiency syndrome	2.71e-05	0.000196	CcSEcCtD
Doxorubicin—Constipation—Lamivudine—acquired immunodeficiency syndrome	2.71e-05	0.000196	CcSEcCtD
Doxorubicin—NOS2—Hemostasis—IFNA1—acquired immunodeficiency syndrome	2.7e-05	0.00296	CbGpPWpGaD
Doxorubicin—Asthenia—Delavirdine—acquired immunodeficiency syndrome	2.68e-05	0.000193	CcSEcCtD
Doxorubicin—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	2.67e-05	0.000193	CcSEcCtD
Doxorubicin—Pruritus—Delavirdine—acquired immunodeficiency syndrome	2.64e-05	0.000191	CcSEcCtD
Doxorubicin—Urticaria—Saquinavir—acquired immunodeficiency syndrome	2.64e-05	0.000191	CcSEcCtD
Doxorubicin—Nausea—Zidovudine—acquired immunodeficiency syndrome	2.64e-05	0.00019	CcSEcCtD
Doxorubicin—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	2.63e-05	0.00019	CcSEcCtD
Doxorubicin—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	2.63e-05	0.00019	CcSEcCtD
Doxorubicin—Vomiting—Indinavir—acquired immunodeficiency syndrome	2.63e-05	0.00019	CcSEcCtD
Doxorubicin—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	2.61e-05	0.000189	CcSEcCtD
Doxorubicin—NOS2—Spinal Cord Injury—TNF—acquired immunodeficiency syndrome	2.61e-05	0.00285	CbGpPWpGaD
Doxorubicin—Rash—Indinavir—acquired immunodeficiency syndrome	2.6e-05	0.000188	CcSEcCtD
Doxorubicin—Dermatitis—Indinavir—acquired immunodeficiency syndrome	2.6e-05	0.000188	CcSEcCtD
Doxorubicin—NOS2—Disease—CCNT1—acquired immunodeficiency syndrome	2.6e-05	0.00284	CbGpPWpGaD
Doxorubicin—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	2.59e-05	0.000187	CcSEcCtD
Doxorubicin—NQO1—Metabolism—AGPS—acquired immunodeficiency syndrome	2.59e-05	0.00284	CbGpPWpGaD
Doxorubicin—Headache—Indinavir—acquired immunodeficiency syndrome	2.59e-05	0.000187	CcSEcCtD
Doxorubicin—Dizziness—Efavirenz—acquired immunodeficiency syndrome	2.58e-05	0.000186	CcSEcCtD
Doxorubicin—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	2.55e-05	0.000184	CcSEcCtD
Doxorubicin—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	2.54e-05	0.000184	CcSEcCtD
Doxorubicin—CYP1B1—Aryl Hydrocarbon Receptor Pathway—TNF—acquired immunodeficiency syndrome	2.53e-05	0.00277	CbGpPWpGaD
Doxorubicin—CYP1B1—Aryl Hydrocarbon Receptor—TNF—acquired immunodeficiency syndrome	2.53e-05	0.00277	CbGpPWpGaD
Doxorubicin—Urticaria—Lamivudine—acquired immunodeficiency syndrome	2.52e-05	0.000182	CcSEcCtD
Doxorubicin—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	2.51e-05	0.000181	CcSEcCtD
Doxorubicin—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	2.51e-05	0.000181	CcSEcCtD
Doxorubicin—AKR1C3—Metabolism—AGPS—acquired immunodeficiency syndrome	2.5e-05	0.00274	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—TAT—acquired immunodeficiency syndrome	2.48e-05	0.00272	CbGpPWpGaD
Doxorubicin—Vomiting—Efavirenz—acquired immunodeficiency syndrome	2.48e-05	0.000179	CcSEcCtD
Doxorubicin—Asthenia—Ritonavir—acquired immunodeficiency syndrome	2.48e-05	0.000179	CcSEcCtD
Doxorubicin—Dizziness—Delavirdine—acquired immunodeficiency syndrome	2.47e-05	0.000178	CcSEcCtD
Doxorubicin—Rash—Efavirenz—acquired immunodeficiency syndrome	2.46e-05	0.000178	CcSEcCtD
Doxorubicin—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	2.46e-05	0.000177	CcSEcCtD
Doxorubicin—Nausea—Indinavir—acquired immunodeficiency syndrome	2.45e-05	0.000177	CcSEcCtD
Doxorubicin—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	2.45e-05	0.000177	CcSEcCtD
Doxorubicin—Headache—Efavirenz—acquired immunodeficiency syndrome	2.44e-05	0.000177	CcSEcCtD
Doxorubicin—Pruritus—Ritonavir—acquired immunodeficiency syndrome	2.44e-05	0.000176	CcSEcCtD
Doxorubicin—AKR1C3—Disease—CCNT1—acquired immunodeficiency syndrome	2.39e-05	0.00261	CbGpPWpGaD
Doxorubicin—Asthenia—Saquinavir—acquired immunodeficiency syndrome	2.38e-05	0.000172	CcSEcCtD
Doxorubicin—Vomiting—Delavirdine—acquired immunodeficiency syndrome	2.37e-05	0.000171	CcSEcCtD
Doxorubicin—NOS3—Disease—APOBEC3G—acquired immunodeficiency syndrome	2.37e-05	0.0026	CbGpPWpGaD
Doxorubicin—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	2.36e-05	0.000171	CcSEcCtD
Doxorubicin—Rash—Delavirdine—acquired immunodeficiency syndrome	2.35e-05	0.00017	CcSEcCtD
Doxorubicin—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	2.35e-05	0.00017	CcSEcCtD
Doxorubicin—Pruritus—Saquinavir—acquired immunodeficiency syndrome	2.35e-05	0.00017	CcSEcCtD
Doxorubicin—Headache—Delavirdine—acquired immunodeficiency syndrome	2.34e-05	0.000169	CcSEcCtD
Doxorubicin—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	2.34e-05	0.000169	CcSEcCtD
Doxorubicin—NOS3—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	2.33e-05	0.00255	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—AGPS—acquired immunodeficiency syndrome	2.32e-05	0.00255	CbGpPWpGaD
Doxorubicin—Nausea—Efavirenz—acquired immunodeficiency syndrome	2.32e-05	0.000167	CcSEcCtD
Doxorubicin—Dizziness—Ritonavir—acquired immunodeficiency syndrome	2.28e-05	0.000165	CcSEcCtD
Doxorubicin—Asthenia—Lamivudine—acquired immunodeficiency syndrome	2.27e-05	0.000164	CcSEcCtD
Doxorubicin—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	2.27e-05	0.000164	CcSEcCtD
Doxorubicin—XDH—Selenium Micronutrient Network—IL6—acquired immunodeficiency syndrome	2.27e-05	0.00249	CbGpPWpGaD
Doxorubicin—Pruritus—Lamivudine—acquired immunodeficiency syndrome	2.24e-05	0.000162	CcSEcCtD
Doxorubicin—NOS1—Myometrial Relaxation and Contraction Pathways—IL6—acquired immunodeficiency syndrome	2.24e-05	0.00245	CbGpPWpGaD
Doxorubicin—Nausea—Delavirdine—acquired immunodeficiency syndrome	2.22e-05	0.00016	CcSEcCtD
Doxorubicin—Dizziness—Saquinavir—acquired immunodeficiency syndrome	2.2e-05	0.000159	CcSEcCtD
Doxorubicin—Vomiting—Ritonavir—acquired immunodeficiency syndrome	2.2e-05	0.000159	CcSEcCtD
Doxorubicin—DHCR7—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	2.19e-05	0.0024	CbGpPWpGaD
Doxorubicin—Rash—Ritonavir—acquired immunodeficiency syndrome	2.18e-05	0.000157	CcSEcCtD
Doxorubicin—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	2.18e-05	0.000157	CcSEcCtD
Doxorubicin—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	2.17e-05	0.000157	CcSEcCtD
Doxorubicin—Headache—Ritonavir—acquired immunodeficiency syndrome	2.16e-05	0.000156	CcSEcCtD
Doxorubicin—ABCC6—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	2.13e-05	0.00233	CbGpPWpGaD
Doxorubicin—ABCB1—Allograft Rejection—IL10—acquired immunodeficiency syndrome	2.12e-05	0.00233	CbGpPWpGaD
Doxorubicin—ABCB1—Allograft Rejection—CD40LG—acquired immunodeficiency syndrome	2.12e-05	0.00233	CbGpPWpGaD
Doxorubicin—Vomiting—Saquinavir—acquired immunodeficiency syndrome	2.11e-05	0.000153	CcSEcCtD
Doxorubicin—NOS3—Metabolism—AGPS—acquired immunodeficiency syndrome	2.11e-05	0.00231	CbGpPWpGaD
Doxorubicin—NOS2—Hemostasis—CSF2—acquired immunodeficiency syndrome	2.11e-05	0.00231	CbGpPWpGaD
Doxorubicin—NOS2—Spinal Cord Injury—IL6—acquired immunodeficiency syndrome	2.1e-05	0.0023	CbGpPWpGaD
Doxorubicin—Dizziness—Lamivudine—acquired immunodeficiency syndrome	2.1e-05	0.000151	CcSEcCtD
Doxorubicin—NOS3—Hemostasis—IFNA1—acquired immunodeficiency syndrome	2.1e-05	0.00229	CbGpPWpGaD
Doxorubicin—Rash—Saquinavir—acquired immunodeficiency syndrome	2.1e-05	0.000151	CcSEcCtD
Doxorubicin—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	2.09e-05	0.000151	CcSEcCtD
Doxorubicin—Headache—Saquinavir—acquired immunodeficiency syndrome	2.08e-05	0.00015	CcSEcCtD
Doxorubicin—ABCB1—Allograft Rejection—IL4—acquired immunodeficiency syndrome	2.07e-05	0.00226	CbGpPWpGaD
Doxorubicin—Nausea—Ritonavir—acquired immunodeficiency syndrome	2.05e-05	0.000148	CcSEcCtD
Doxorubicin—YWHAG—Apoptosis—TNF—acquired immunodeficiency syndrome	2.05e-05	0.00224	CbGpPWpGaD
Doxorubicin—CBR1—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	2.04e-05	0.00224	CbGpPWpGaD
Doxorubicin—YWHAG—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	2.04e-05	0.00223	CbGpPWpGaD
Doxorubicin—ABCB1—Allograft Rejection—HLA-B—acquired immunodeficiency syndrome	2.02e-05	0.00221	CbGpPWpGaD
Doxorubicin—NOS3—Disease—CCNT1—acquired immunodeficiency syndrome	2.02e-05	0.00221	CbGpPWpGaD
Doxorubicin—Vomiting—Lamivudine—acquired immunodeficiency syndrome	2.02e-05	0.000146	CcSEcCtD
Doxorubicin—ABCB11—Metabolism—TAT—acquired immunodeficiency syndrome	2.02e-05	0.00221	CbGpPWpGaD
Doxorubicin—Rash—Lamivudine—acquired immunodeficiency syndrome	2e-05	0.000144	CcSEcCtD
Doxorubicin—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	2e-05	0.000144	CcSEcCtD
Doxorubicin—Headache—Lamivudine—acquired immunodeficiency syndrome	1.99e-05	0.000143	CcSEcCtD
Doxorubicin—Nausea—Saquinavir—acquired immunodeficiency syndrome	1.97e-05	0.000143	CcSEcCtD
Doxorubicin—ABCC3—Metabolism—TAT—acquired immunodeficiency syndrome	1.93e-05	0.00212	CbGpPWpGaD
Doxorubicin—Nausea—Lamivudine—acquired immunodeficiency syndrome	1.88e-05	0.000136	CcSEcCtD
Doxorubicin—RALBP1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.86e-05	0.00204	CbGpPWpGaD
Doxorubicin—ABCC10—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.86e-05	0.00203	CbGpPWpGaD
Doxorubicin—NOS1—Hemostasis—ALB—acquired immunodeficiency syndrome	1.82e-05	0.002	CbGpPWpGaD
Doxorubicin—NOS1—Disease—CXCR4—acquired immunodeficiency syndrome	1.81e-05	0.00198	CbGpPWpGaD
Doxorubicin—NOS3—VEGFA-VEGFR2 Pathway—IL6—acquired immunodeficiency syndrome	1.77e-05	0.00193	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—AGPS—acquired immunodeficiency syndrome	1.71e-05	0.00188	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.69e-05	0.00185	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.67e-05	0.00183	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.67e-05	0.00183	CbGpPWpGaD
Doxorubicin—NOS3—Signaling by VEGF—IL6—acquired immunodeficiency syndrome	1.67e-05	0.00182	CbGpPWpGaD
Doxorubicin—YWHAG—Myometrial Relaxation and Contraction Pathways—IL6—acquired immunodeficiency syndrome	1.65e-05	0.00181	CbGpPWpGaD
Doxorubicin—YWHAG—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	1.64e-05	0.0018	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—AGPS—acquired immunodeficiency syndrome	1.64e-05	0.0018	CbGpPWpGaD
Doxorubicin—NOS3—Hemostasis—CSF2—acquired immunodeficiency syndrome	1.64e-05	0.0018	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.58e-05	0.00174	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.58e-05	0.00174	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—TAT—acquired immunodeficiency syndrome	1.51e-05	0.00166	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.51e-05	0.00166	CbGpPWpGaD
Doxorubicin—NOS1—Hemostasis—IL2—acquired immunodeficiency syndrome	1.48e-05	0.00162	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—TAT—acquired immunodeficiency syndrome	1.46e-05	0.0016	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—APOBEC3G—acquired immunodeficiency syndrome	1.45e-05	0.00158	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.41e-05	0.00155	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.41e-05	0.00155	CbGpPWpGaD
Doxorubicin—NOS2—Hemostasis—ALB—acquired immunodeficiency syndrome	1.38e-05	0.00151	CbGpPWpGaD
Doxorubicin—NOS2—Circadian rythm related genes—IL6—acquired immunodeficiency syndrome	1.37e-05	0.0015	CbGpPWpGaD
Doxorubicin—NOS2—Disease—CXCR4—acquired immunodeficiency syndrome	1.36e-05	0.00149	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—TAT—acquired immunodeficiency syndrome	1.33e-05	0.00146	CbGpPWpGaD
Doxorubicin—NOS3—Myometrial Relaxation and Contraction Pathways—IL6—acquired immunodeficiency syndrome	1.31e-05	0.00144	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—AGPS—acquired immunodeficiency syndrome	1.29e-05	0.00141	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.28e-05	0.0014	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—CXCR4—acquired immunodeficiency syndrome	1.25e-05	0.00137	CbGpPWpGaD
Doxorubicin—ABCB1—Allograft Rejection—IFNG—acquired immunodeficiency syndrome	1.25e-05	0.00137	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—AGPS—acquired immunodeficiency syndrome	1.25e-05	0.00136	CbGpPWpGaD
Doxorubicin—NOS1—Disease—CCR5—acquired immunodeficiency syndrome	1.24e-05	0.00136	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—CCNT1—acquired immunodeficiency syndrome	1.23e-05	0.00135	CbGpPWpGaD
Doxorubicin—NDUFS7—Metabolism—ALB—acquired immunodeficiency syndrome	1.22e-05	0.00134	CbGpPWpGaD
Doxorubicin—NDUFS3—Metabolism—ALB—acquired immunodeficiency syndrome	1.22e-05	0.00134	CbGpPWpGaD
Doxorubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	1.21e-05	0.00133	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.21e-05	0.00132	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.19e-05	0.0013	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.15e-05	0.00126	CbGpPWpGaD
Doxorubicin—NDUFS2—Metabolism—ALB—acquired immunodeficiency syndrome	1.15e-05	0.00126	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—AGPS—acquired immunodeficiency syndrome	1.13e-05	0.00124	CbGpPWpGaD
Doxorubicin—NOS2—Hemostasis—IL2—acquired immunodeficiency syndrome	1.12e-05	0.00122	CbGpPWpGaD
Doxorubicin—ABCB1—Allograft Rejection—IL2—acquired immunodeficiency syndrome	1.11e-05	0.00122	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.09e-05	0.00119	CbGpPWpGaD
Doxorubicin—NOS3—Hemostasis—ALB—acquired immunodeficiency syndrome	1.07e-05	0.00117	CbGpPWpGaD
Doxorubicin—NOS3—Disease—CXCR4—acquired immunodeficiency syndrome	1.06e-05	0.00116	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.03e-05	0.00113	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—TAT—acquired immunodeficiency syndrome	9.77e-06	0.00107	CbGpPWpGaD
Doxorubicin—DHCR7—Metabolism—ALB—acquired immunodeficiency syndrome	9.76e-06	0.00107	CbGpPWpGaD
Doxorubicin—TOP2A—Circadian rythm related genes—IL6—acquired immunodeficiency syndrome	9.39e-06	0.00103	CbGpPWpGaD
Doxorubicin—NOS2—Disease—CCR5—acquired immunodeficiency syndrome	9.35e-06	0.00102	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	9.34e-06	0.00102	CbGpPWpGaD
Doxorubicin—CBR1—Metabolism—ALB—acquired immunodeficiency syndrome	9.11e-06	0.000997	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	8.78e-06	0.000961	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	8.78e-06	0.000961	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	8.73e-06	0.000955	CbGpPWpGaD
Doxorubicin—NOS3—Hemostasis—IL2—acquired immunodeficiency syndrome	8.67e-06	0.000949	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—CCR5—acquired immunodeficiency syndrome	8.59e-06	0.000941	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—AGPS—acquired immunodeficiency syndrome	8.3e-06	0.000909	CbGpPWpGaD
Doxorubicin—ABCB1—Allograft Rejection—TNF—acquired immunodeficiency syndrome	8.08e-06	0.000885	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	7.89e-06	0.000864	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	7.89e-06	0.000864	CbGpPWpGaD
Doxorubicin—NOS1—Disease—CD4—acquired immunodeficiency syndrome	7.79e-06	0.000853	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	7.57e-06	0.000829	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	7.42e-06	0.000812	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	7.42e-06	0.000812	CbGpPWpGaD
Doxorubicin—NOS3—Disease—CCR5—acquired immunodeficiency syndrome	7.26e-06	0.000795	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—TAT—acquired immunodeficiency syndrome	7.2e-06	0.000789	CbGpPWpGaD
Doxorubicin—ABCC3—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	7.19e-06	0.000788	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—TAT—acquired immunodeficiency syndrome	6.79e-06	0.000743	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	6.68e-06	0.000731	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	6.58e-06	0.00072	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—CXCR4—acquired immunodeficiency syndrome	6.46e-06	0.000707	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	6.28e-06	0.000687	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—AGPS—acquired immunodeficiency syndrome	6.13e-06	0.000671	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	6.02e-06	0.000659	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	5.93e-06	0.000649	CbGpPWpGaD
Doxorubicin—NOS2—Disease—CD4—acquired immunodeficiency syndrome	5.87e-06	0.000643	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—AGPS—acquired immunodeficiency syndrome	5.77e-06	0.000632	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	5.73e-06	0.000628	CbGpPWpGaD
Doxorubicin—ABCC2—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	5.7e-06	0.000625	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	5.64e-06	0.000618	CbGpPWpGaD
Doxorubicin—ABCC1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	5.64e-06	0.000617	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	5.56e-06	0.000609	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—CD4—acquired immunodeficiency syndrome	5.4e-06	0.000591	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—ALB—acquired immunodeficiency syndrome	5.32e-06	0.000582	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—ALB—acquired immunodeficiency syndrome	5.13e-06	0.000562	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	5.09e-06	0.000557	CbGpPWpGaD
Doxorubicin—ABCG2—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	4.96e-06	0.000543	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—ALB—acquired immunodeficiency syndrome	4.77e-06	0.000522	CbGpPWpGaD
Doxorubicin—NOS3—Disease—CD4—acquired immunodeficiency syndrome	4.56e-06	0.000499	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	4.44e-06	0.000486	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—CCR5—acquired immunodeficiency syndrome	4.42e-06	0.000485	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—ALB—acquired immunodeficiency syndrome	4.33e-06	0.000474	CbGpPWpGaD
Doxorubicin—NOS1—Disease—IL6—acquired immunodeficiency syndrome	4.21e-06	0.000461	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	3.99e-06	0.000437	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	3.77e-06	0.000413	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.69e-06	0.000404	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—ALB—acquired immunodeficiency syndrome	3.51e-06	0.000385	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.48e-06	0.000381	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—ALB—acquired immunodeficiency syndrome	3.37e-06	0.000369	CbGpPWpGaD
Doxorubicin—NOS2—Disease—IL6—acquired immunodeficiency syndrome	3.18e-06	0.000348	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.94e-06	0.000322	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—IL6—acquired immunodeficiency syndrome	2.92e-06	0.00032	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—CD4—acquired immunodeficiency syndrome	2.78e-06	0.000304	CbGpPWpGaD
Doxorubicin—ABCB1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	2.68e-06	0.000294	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—ALB—acquired immunodeficiency syndrome	2.64e-06	0.000289	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—ALB—acquired immunodeficiency syndrome	2.55e-06	0.00028	CbGpPWpGaD
Doxorubicin—NOS3—Disease—IL6—acquired immunodeficiency syndrome	2.47e-06	0.00027	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—ALB—acquired immunodeficiency syndrome	2.32e-06	0.000254	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.04e-06	0.000224	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.73e-06	0.000189	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—ALB—acquired immunodeficiency syndrome	1.7e-06	0.000186	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—IL6—acquired immunodeficiency syndrome	1.5e-06	0.000165	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—ALB—acquired immunodeficiency syndrome	1.26e-06	0.000138	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—ALB—acquired immunodeficiency syndrome	1.18e-06	0.00013	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	7.74e-07	8.47e-05	CbGpPWpGaD
